However, when single monoclonal antibodies are administered, immune-related side effects are common, and due to their large molecular weight, poor permeability to tumor tissue after administration, and unsatisfactory treatment effect, most PD-1-related mAbs are available commercially via PD-L1 treatment of tumors. The gene discussed is PDCD1; the disease is neoplasm.